{"entity":"novo-nordisk","name":"Novo Nordisk","kind":"money","summary":"Novo Nordisk's timeline holds 42 money & deals claims from 2018 to 2025. The latest took effect on December 31, 2025.","counts":{"total":55,"by_kind":{"people":2,"money":42,"products":0,"models":0,"other":11}},"events":[{"date":"2018-12-31","until":"2019-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 51,839,000,000 DKK\", as of 2018-12-31 (until 2019-12-31). Claim clm_3322844F3158, https://asof.is/claim/clm_3322844F3158, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_3322844F3158","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"51,839,000,000 DKK","status":"superseded","assertable":true,"id":"clm_3322844F3158","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"date":"2019-12-31","until":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 43,258 employee\", as of 2019-12-31 (until 2020-12-31). Claim clm_277344156E80, https://asof.is/claim/clm_277344156E80, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_277344156E80","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"43,258 employee","status":"superseded","assertable":true,"id":"clm_277344156E80","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2021, filed 2022-02-02"}},{"date":"2019-12-31","until":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 57,593,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_43C7BF9EE087, https://asof.is/claim/clm_43C7BF9EE087, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_43C7BF9EE087","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"57,593,000,000 DKK","status":"superseded","assertable":true,"id":"clm_43C7BF9EE087","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"date":"2019-12-31","until":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 52,483,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_B2B75C38DC99, https://asof.is/claim/clm_B2B75C38DC99, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_B2B75C38DC99","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"52,483,000,000 DKK","status":"superseded","assertable":true,"id":"clm_B2B75C38DC99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-02"}},{"date":"2019-12-31","until":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 38,951,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_DA4855A5F51A, https://asof.is/claim/clm_DA4855A5F51A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_DA4855A5F51A","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"38,951,000,000 DKK","status":"superseded","assertable":true,"id":"clm_DA4855A5F51A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-02"}},{"date":"2019-12-31","until":"2020-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 122,021,000,000 DKK\", as of 2019-12-31 (until 2020-12-31). Claim clm_F0275DE8A21D, https://asof.is/claim/clm_F0275DE8A21D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_F0275DE8A21D","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"122,021,000,000 DKK","status":"superseded","assertable":true,"id":"clm_F0275DE8A21D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-02"}},{"date":"2020-12-31","until":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 144,922,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_072CD0878EE5, https://asof.is/claim/clm_072CD0878EE5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_072CD0878EE5","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"144,922,000,000 DKK","status":"superseded","assertable":true,"id":"clm_072CD0878EE5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2021, filed 2022-02-02"}},{"date":"2020-12-31","until":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 42,138,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_2112055E65B9, https://asof.is/claim/clm_2112055E65B9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_2112055E65B9","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"42,138,000,000 DKK","status":"superseded","assertable":true,"id":"clm_2112055E65B9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-02"}},{"date":"2020-12-31","until":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 45,323 employee\", as of 2020-12-31 (until 2021-12-31). Claim clm_5D92621F8B64, https://asof.is/claim/clm_5D92621F8B64, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_5D92621F8B64","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"45,323 employee","status":"superseded","assertable":true,"id":"clm_5D92621F8B64","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2021, filed 2022-02-02"}},{"date":"2020-12-31","until":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 126,946,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_67D64D48F06E, https://asof.is/claim/clm_67D64D48F06E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_67D64D48F06E","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"126,946,000,000 DKK","status":"superseded","assertable":true,"id":"clm_67D64D48F06E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-02"}},{"date":"2020-12-31","until":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 54,126,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_D272A9AE2D76, https://asof.is/claim/clm_D272A9AE2D76, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_D272A9AE2D76","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"54,126,000,000 DKK","status":"superseded","assertable":true,"id":"clm_D272A9AE2D76","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-02"}},{"date":"2020-12-31","until":"2021-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 63,325,000,000 DKK\", as of 2020-12-31 (until 2021-12-31). Claim clm_D44DDD0D515C, https://asof.is/claim/clm_D44DDD0D515C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_D44DDD0D515C","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,325,000,000 DKK","status":"superseded","assertable":true,"id":"clm_D44DDD0D515C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 70,746,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_1B204B243A08, https://asof.is/claim/clm_1B204B243A08, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_1B204B243A08","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"70,746,000,000 DKK","status":"superseded","assertable":true,"id":"clm_1B204B243A08","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2021, filed 2022-02-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 58,644,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_4E462623C749, https://asof.is/claim/clm_4E462623C749, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_4E462623C749","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"58,644,000,000 DKK","status":"superseded","assertable":true,"id":"clm_4E462623C749","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2021, filed 2022-02-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 194,508,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_6D30A77C658F, https://asof.is/claim/clm_6D30A77C658F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_6D30A77C658F","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"194,508,000,000 DKK","status":"superseded","assertable":true,"id":"clm_6D30A77C658F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2021, filed 2022-02-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 48,478 employee\", as of 2021-12-31 (until 2022-12-31). Claim clm_71916DF751CE, https://asof.is/claim/clm_71916DF751CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_71916DF751CE","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"48,478 employee","status":"superseded","assertable":true,"id":"clm_71916DF751CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2021, filed 2022-02-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 47,757,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_8F5ADB2C07ED, https://asof.is/claim/clm_8F5ADB2C07ED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_8F5ADB2C07ED","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"47,757,000,000 DKK","status":"superseded","assertable":true,"id":"clm_8F5ADB2C07ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2021, filed 2022-02-02"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 140,800,000,000 DKK\", as of 2021-12-31 (until 2022-12-31). Claim clm_DEF63B463032, https://asof.is/claim/clm_DEF63B463032, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828022001639/0001628280-22-001639-index.htm.","url":"https://asof.is/claim/clm_DEF63B463032","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"140,800,000,000 DKK","status":"superseded","assertable":true,"id":"clm_DEF63B463032","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2021, filed 2022-02-02"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 55,525,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_1A208DF6F487, https://asof.is/claim/clm_1A208DF6F487, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_1A208DF6F487","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"55,525,000,000 DKK","status":"superseded","assertable":true,"id":"clm_1A208DF6F487","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2022, filed 2023-02-01"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 176,954,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_459BEEC0AB43, https://asof.is/claim/clm_459BEEC0AB43, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_459BEEC0AB43","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"176,954,000,000 DKK","status":"superseded","assertable":true,"id":"clm_459BEEC0AB43","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2022, filed 2023-02-01"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 241,257,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_56708B41C767, https://asof.is/claim/clm_56708B41C767, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_56708B41C767","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"241,257,000,000 DKK","status":"superseded","assertable":true,"id":"clm_56708B41C767","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2022, filed 2023-02-01"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 83,486,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_800F88E2D840, https://asof.is/claim/clm_800F88E2D840, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_800F88E2D840","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"83,486,000,000 DKK","status":"superseded","assertable":true,"id":"clm_800F88E2D840","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2022, filed 2023-02-01"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 55,185 employee\", as of 2022-12-31 (until 2023-12-31). Claim clm_D62CD294DD73, https://asof.is/claim/clm_D62CD294DD73, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_D62CD294DD73","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"55,185 employee","status":"superseded","assertable":true,"id":"clm_D62CD294DD73","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2022, filed 2023-02-01"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 74,809,000,000 DKK\", as of 2022-12-31 (until 2023-12-31). Claim clm_F3418E0D3161, https://asof.is/claim/clm_F3418E0D3161, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828023001868/0001628280-23-001868-index.htm.","url":"https://asof.is/claim/clm_F3418E0D3161","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"74,809,000,000 DKK","status":"superseded","assertable":true,"id":"clm_F3418E0D3161","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2022, filed 2023-02-01"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 64,319 employee\", as of 2023-12-31 (until 2024-12-31). Claim clm_5B1E4C20C74E, https://asof.is/claim/clm_5B1E4C20C74E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_5B1E4C20C74E","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"64,319 employee","status":"superseded","assertable":true,"id":"clm_5B1E4C20C74E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2023, filed 2024-01-31"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 102,574,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_792EA3966BEF, https://asof.is/claim/clm_792EA3966BEF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_792EA3966BEF","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"102,574,000,000 DKK","status":"superseded","assertable":true,"id":"clm_792EA3966BEF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2023, filed 2024-01-31"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 232,261,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_8ED842A2DCE7, https://asof.is/claim/clm_8ED842A2DCE7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_8ED842A2DCE7","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"232,261,000,000 DKK","status":"superseded","assertable":true,"id":"clm_8ED842A2DCE7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2023, filed 2024-01-31"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 314,486,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_A36685A1C540, https://asof.is/claim/clm_A36685A1C540, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_A36685A1C540","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"314,486,000,000 DKK","status":"superseded","assertable":true,"id":"clm_A36685A1C540","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2023, filed 2024-01-31"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 106,561,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_A40D8D2F280A, https://asof.is/claim/clm_A40D8D2F280A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_A40D8D2F280A","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"106,561,000,000 DKK","status":"superseded","assertable":true,"id":"clm_A40D8D2F280A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2023, filed 2024-01-31"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-01-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 83,683,000,000 DKK\", as of 2023-12-31 (until 2024-12-31). Claim clm_A49F4F076521, https://asof.is/claim/clm_A49F4F076521, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828024002635/0001628280-24-002635-index.htm.","url":"https://asof.is/claim/clm_A49F4F076521","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"83,683,000,000 DKK","status":"superseded","assertable":true,"id":"clm_A49F4F076521","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2023, filed 2024-01-31"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 128,339,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_109041F6F3C0, https://asof.is/claim/clm_109041F6F3C0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_109041F6F3C0","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"128,339,000,000 DKK","status":"superseded","assertable":true,"id":"clm_109041F6F3C0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 465,795,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_36763BC50C4E, https://asof.is/claim/clm_36763BC50C4E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_36763BC50C4E","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"465,795,000,000 DKK","status":"superseded","assertable":true,"id":"clm_36763BC50C4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 143,486,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_4145313CD790, https://asof.is/claim/clm_4145313CD790, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_4145313CD790","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"143,486,000,000 DKK","status":"superseded","assertable":true,"id":"clm_4145313CD790","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 77,349 employee\", as of 2024-12-31 (until 2025-12-31). Claim clm_6A7CC2B7840B, https://asof.is/claim/clm_6A7CC2B7840B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_6A7CC2B7840B","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"77,349 employee","status":"superseded","assertable":true,"id":"clm_6A7CC2B7840B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 100,988,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_8A5C5EE097FD, https://asof.is/claim/clm_8A5C5EE097FD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_8A5C5EE097FD","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"100,988,000,000 DKK","status":"superseded","assertable":true,"id":"clm_8A5C5EE097FD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2024, filed 2025-02-05"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 290,403,000,000 DKK\", as of 2024-12-31 (until 2025-12-31). Claim clm_A3B9347CE850, https://asof.is/claim/clm_A3B9347CE850, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000162828025003920/0001628280-25-003920-index.htm.","url":"https://asof.is/claim/clm_A3B9347CE850","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"290,403,000,000 DKK","status":"superseded","assertable":true,"id":"clm_A3B9347CE850","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2024, filed 2025-02-05"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total equity: 194,047,000,000 DKK\", as of 2025-12-31. Claim clm_51EBABE50856, https://asof.is/claim/clm_51EBABE50856, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_51EBABE50856","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"194,047,000,000 DKK","status":"valid","assertable":true,"id":"clm_51EBABE50856","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Equity in 20-F FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk operating income: 127,658,000,000 DKK\", as of 2025-12-31. Claim clm_672756B8F8A9, https://asof.is/claim/clm_672756B8F8A9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_672756B8F8A9","accessed":"2026-11-10"},"kind":"money","predicate":"operating_income","value":"127,658,000,000 DKK","status":"valid","assertable":true,"id":"clm_672756B8F8A9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLossFromOperatingActivities in 20-F FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk employees: 69,505 employee\", as of 2025-12-31. Claim clm_8EB909BEF688, https://asof.is/claim/clm_8EB909BEF688, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_8EB909BEF688","accessed":"2026-11-10"},"kind":"money","predicate":"employees","value":"69,505 employee","status":"valid","assertable":true,"id":"clm_8EB909BEF688","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityNumberOfEmployees in 20-F FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk revenue: 309,064,000,000 DKK\", as of 2025-12-31. Claim clm_8F7EC31D7FFC, https://asof.is/claim/clm_8F7EC31D7FFC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_8F7EC31D7FFC","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"309,064,000,000 DKK","status":"valid","assertable":true,"id":"clm_8F7EC31D7FFC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Revenue in 20-F FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk total assets: 542,902,000,000 DKK\", as of 2025-12-31. Claim clm_BCB17EC648AA, https://asof.is/claim/clm_BCB17EC648AA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_BCB17EC648AA","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"542,902,000,000 DKK","status":"valid","assertable":true,"id":"clm_BCB17EC648AA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:Assets in 20-F FY2025, filed 2026-02-04"}},{"date":"2025-12-31","until":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Novo Nordisk net income: 102,434,000,000 DKK\", as of 2025-12-31. Claim clm_F536BDE429B7, https://asof.is/claim/clm_F536BDE429B7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm.","url":"https://asof.is/claim/clm_F536BDE429B7","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"102,434,000,000 DKK","status":"valid","assertable":true,"id":"clm_F536BDE429B7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"ifrs-full:ProfitLoss in 20-F FY2025, filed 2026-02-04"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}